Very few substitutions in a germ line antibody are required to initiate significant domain exchange

Journal of Virology

Volumn 84, Issue 20, 2010, Pages 10700-10707

  Huber, Michael ^a,b   Le, Khoa M ^a   Doores, Katie J ^a,b   Fulton, Zara ^a   Stanfield, Robyn L ^a   Wilson, Ian A ^a   Burton, Dennis R ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY 2G12;

ANTIBODY STRUCTURE; ARTICLE; BINDING SITE; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; SUBSTITUTION LINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77957201600     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01111-10     Document Type: Article

References (46)

1. Astronomo, R. D., and D. R. Burton. 2010. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat. Rev. Drug Discov. 9:308-324.
2. Batista, F. D., and M. S. Neuberger. 1998. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity 8:751-759.
3. Bebbington, C. R., G. Renner, S. Thomson, D. King, D. Abrams, and G. T. Yarranton. 1992. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology (N. Y.) 10:169-175.
4. Bennett, M. J., M. R. Sawaya, and D. Eisenberg. 2006. Deposition diseases and 3D domain swapping. Structure 14:811-824.
5. Binley, J. M., T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C. Petropoulos, and D. R. Burton. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252.
6. Brochet, X., M.-P. Lefranc, and V. Giudicelli. 2008. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36:W503-W508.
7. Buchacher, A., R. Predl, K. Strutzenberger, W. Steinfellner, A. Trkola, M. Purtscher, G. Gruber, C. Tauer, F. Steindl, A. Jungbauer, et al. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10:359-369.
8. Burton, D. R., R. Desrosiers, R. Doms, W. Koff, P. Kwong, J. Moore, G. Nabel, J. Sodroski, I. Wilson, and R. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236.
9. Burton, D. R., J. Pyati, R. Koduri, S. Sharp, G. Thornton, P. Parren, L. Sawyer, R. Hendry, N. Dunlop, and P. Nara. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
10. Calarese, D., H. Lee, C. Huang, M. Best, R. D. Astronomo, R. Stanfield, H. Katinger, D. R. Burton, C. Wong, and I. Wilson. 2005. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. U. S. A. 102:13372-13377.
11. Calarese, D. A., C. N. Scanlan, M. B. Zwick, S. Deechongkit, Y. Mimura, R. Kunert, P. Zhu, M. R. Wormald, R. L. Stanfield, K. H. Roux, J. W. Kelly, P. M. Rudd, R. A. Dwek, H. Katinger, D. R. Burton, and I. A. Wilson. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-2071.
12. Dal Porto, J. M., A. M. Haberman, M. J. Shlomchik, and G. Kelsoe. 1998. Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. J. Immunol. 161:5373-5381.
13. Doores, K. J., Z. Fulton, M. Huber, I. A. Wilson, and D. R. Burton. 2010. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain- exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J. Virol. 84:10690-10699.
14. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
15. Feige, M. J., S. Groscurth, M. Marcinowski, Y. Shimizu, H. Kessler, L. M. Hendershot, and J. Buchner. 2009. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol. Cell 34:569-579.
16. Gach, J. S., P. G. Furtmüller, H. Quendler, P. Messner, R. Wagner, H. Katinger, and R. Kunert. 2010. Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1. J. Biol. Chem. 285:1122-1127.
17. Gronenborn, A. M. 2009. Protein acrobatics in pairs - dimerization via domain swapping. Curr. Opin. Struct. Biol. 19:39-49.
18. Haynes, B., and D. Montefiori. 2006. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5:347-363. (Pubitemid 44167156)
19. Hessell, A. J., E. G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D. N. Forthal, W. C. Koff, D. I. Watkins, and D. R. Burton. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433.
20. Huang, C.-C., M. Venturi, S. Majeed, M. J. Moore, S. Phogat, M.-Y. Zhang, D. S. Dimitrov, W. A. Hendrickson, J. Robinson, J. Sodroski, R. Wyatt, H. Choe, M. Farzan, and P. D. Kwong. 2004. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor- binding site on gp120. Proc. Natl. Acad. Sci. U. S. A. 101:2706-2711.
21. Johnston, M. I., and A. S. Fauci. 2007. An HIV vaccine - evolving concepts. N. Engl. J. Med. 356:2073-2081.
22. Joyce, J. G., I. J. Krauss, H. C. Song, D. W. Opalka, K. M. Grimm, D. D. Nahas, M. T. Esser, R. Hrin, M. Feng, V. Y. Dudkin, M. Chastain, J. W. Shiver, and S. J. Danishefsky. 2008. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. Proc. Natl. Acad. Sci. U. S. A. 105:15684-15689.
23. Kabat, E. A., T. T. Wu, H. Bilofsky, M. Reid-Miller, and H. M. Perry. 1983. Sequences of proteins of immunological interest. National Institutes of Health, Bethesda, MD.
24. Kaloff, C. R., and I. G. Haas. 1995. Coordination of immunoglobulin chain folding and immunoglobulin chain assembly is essential for the formation of functional IgG. Immunity 2:629-637.
25. Kunert, R., F. Ruker, and H. Katinger. 1998. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res. 14:1115-1128.
26. Letvin, N. L. 2006. Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol. 6:930-939.
27. Liu, Y., and D. Eisenberg. 2002. 3D domain swapping: as domains continue to swap. Protein Sci. 11:1285-1299. (Pubitemid 34547201)
28. López-Alonso, J. P., G. Gotte, and D. V. Laurents. 2009. Kinetic analysis provides insight into the mechanism of ribonuclease A oligomer formation. Arch. Biochem. Biophys. 489:41-47.
29. Luallen, R. J., C. Agrawal-Gamse, H. Fu, D. F. Smith, R. W. Doms, and Y. Geng. 2010. Antibodies against Manα1,2-Manα1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains. Glycobiology 20:280-286.
30. Mascola, J. R., and D. C. Montefiori. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-444.
31. Mascola, J. R., G. Stiegler, T. C. VanCott, H. Katinger, C. B. Carpenter, C. E. Hanson, H. Beary, D. Hayes, S. S. Frankel, D. L. Birx, and M. G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
32. McMichael, A. J. 2006. HIV vaccines. Annu. Rev. Immunol. 24:227-255.
33. Rousseau, F., J. W. Schymkowitz, H. R. Wilkinson, and L. S. Itzhaki. 2001. Three-dimensional domain swapping in p13suc1 occurs in the unfolded state and is controlled by conserved proline residues. Proc. Natl. Acad. Sci. U. S. A. 98:5596-5601.
34. Roux, K. H., P. Zhu, M. Seavy, H. Katinger, R. Kunert, and V. Seamon. 2004. Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12. Mol. Immunol. 41: 1001-1011.
35. Sanders, R. W., M. Venturi, L. Schiffner, R. Kalyanaraman, H. Katinger, K. O. Lloyd, P. D. Kwong, and J. P. Moore. 2002. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76:7293-7305.
36. Scanlan, C. N., R. Pantophlet, M. R. Wormald, E. Ollmann Saphire, R. Stanfield, I. A. Wilson, H. Katinger, R. A. Dwek, P. M. Rudd, and D. R. Burton. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1->2 mannose residues on the outer face of gp120. J. Virol. 76:7306-7321.
37. Scheid, J. F., H. Mouquet, N. Feldhahn, M. S. Seaman, K. Velinzon, J. Pietzsch, R. G. Ott, R. M. Anthony, H. Zebroski, A. Hurley, A. Phogat, B. K. Chakrabarti, Y. Li, M. Connors, F. Pereyra, B. D. Walker, H. Wardemann, D. Ho, R. T. Wyatt, J. R. Mascola, J. V. Ravetch, and M. C. Nussenzweig. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
38. Tiller, T., E. Meffre, S. Yurasov, M. Tsuiji, M. C. Nussenzweig, and H. Wardemann. 2008. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329:112-124. (Pubitemid 350235462)
39. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, R. Weber, G. Stiegler, B. Vcelar, H. Katinger, L. Aceto, and H. F. Gunthard. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622.
40. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway, H. Katinger, C. F. Barbas III, D. R. Burton, D. D. Ho, et al. 1995. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
41. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108. (Pubitemid 26029030)
42. Virgin, H. W., and B. D. Walker. 2010. Immunology and the elusive AIDS vaccine. Nature 464:224-231.
43. Walker, L. M., S. K. Phogat, P.-Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey, P. W. Hammond, P. G. P. Investigators, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard, and D. R. Burton. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
44. Wang, L.-X. 2006. Toward oligosaccharide- and glycopeptide-based HIV vaccines. Curr. Opin. Drug Discov. Devel. 9:194-206.
45. West, A. P., Jr., R. P. Galimidi, C. P. Foglesong, P. N. Gnanapragasam, K. E. Huey-Tubman, J. S. Klein, M. D. Suzuki, N. E. Tiangco, J. Vielmetter, and P. J. Bjorkman. 2009. Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J. Virol. 83:98-104.
46. Xiao, X., W. Chen, Y. Feng, Z. Zhu, P. Prabakaran, Y. Wang, M.-Y. Zhang, N. S. Longo, and D. S. Dimitrov. 2009. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390:404-409.